On March 24, 2026, the Drug Administration of Vietnam (Ministry of Health) issued an urgent nationwide recall for a specific batch of Aclon, a pain reliever and anti-inflammatory drug manufactured by Shinpoong Daewoo Pharmaceutical Co., Ltd. The product was identified with a Grade 2 violation, indicating a risk that it may not provide full therapeutic efficacy.
Details of the recalled medication batch:
-
Product Name: Aclon film-coated tablets (Aceclofenac 100mg).
-
Registration No.: VD-18521-13.
-
Batch No.: ACT3003; Mfg Date: 04/28/23; Exp Date: 04/27/26.
-
Reason for Recall: Grade 2 violation (evidence of inadequate therapeutic efficacy or potential safety risks that are not yet life-threatening).
Urgent enforcement actions:
-
For the Manufacturer: Shinpoong Daewoo must cease trading, quarantine the affected stock, and coordinate with relevant parties to complete the total recall within 15 days effective from March 23. The company is responsible for all recall costs and legal compensation.
-
For Healthcare Facilities and Users: Hospitals, pharmacies, and patients must immediately stop prescribing, selling, and using the aforementioned batch and return the medication to their suppliers.
-
For Regulatory Authorities: The Dong Nai Department of Health is tasked with directly supervising the disposal process and evaluating the effectiveness of the recall to ensure the product is completely removed from the market.
Aclon is widely used for treating musculoskeletal issues; therefore, this recall is a critical measure to ensure patient safety against substandard pharmaceutical batches.